Skip Ribbon Commands
Skip to main content
Sign In
Navigate Up

25401 BCR/ABL, p210, RT-PCR(BCRAB)

BCR/ABL, p210, RT-PCR(BCRAB)
Test Code: BCRAMSO
Synonyms/Keywords
Acute lymphoblastic leukemia (ALL)
Acute myeloid leukemia (AML)
B lymphoblastic leukemia (B-ALL)
T lymphoblastic leukemia (T-ALL)
BCR-ABL1
BCR ABL
BCR/ABL
Chronic myelogenous leukemia (CML)
Philadelphia chromosome, Ph bone marrow/blood
t(9;22)
Tyrosine kinase inhibitor (TKI) therapy monitoring, PCR
Useful For
​MONITORING response to therapy in patients with chronic myeloid leukemia who are known to have the e13/a2 or e14/a2 BCR/ABL 1 fusion transcript forms
Specimen Requirements
Fasting Required Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)		 Pediatric Minimum Volume
​​(no repeat)
​​​No ​Whole Blood ​EDTA Lavender Top Tube (LTT) ​ACD Yellow Top Tube ​10 ml ​4 mL ​
​                                                                                        OR
​No ​Bone Marrow ​EDTA Lavender Top Tube (LTT) ​ACD Yellow Top Tube ​3 mL ​1 mL ​
Collection Processing Instructions

*Due to short sample stability, DO NOT collect at a regional center on a Friday.  If collected in Marshfield on Friday, only an AM morning draw is acceptable.

Specimen MUST ARRIVE within 72 hours of collection.​ Collect and package specimen as close to shipping time as possible. Specimens greater than 3 days old at the time of receipt will be considered unacceptable.

The following information is required:

1. Pertinent clinical history including if the patient has a diagnosis of chronic myeloid leukemia or other BCR/ABL1-positive neoplasm

2. Date of collection

3. Specimen source (blood or bone marrow)

Acceptable Specimen Types
​Whole Blood OR Bone Marrow
Specimen Stability Information
Specimen Type Temperature Time​​

​Whole Blood

OR

Bone Marrow

​

​Refrigerated

(preferred)

 ​72 hours
​Room Temperature ​72 hours
Rejection Criteria
Whole Blood Gross Hemolysis​​
Bone Marrow​ ​Gross Hemolysis
Performing Laboratory Information
Performing Location Day(s) Test Performed Report Available Methodology/Instrumentation​​
Mayo Clinic Laboratories​ ​Monday through Friday ​3 to 6 days Quantitative Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
Reference Lab
Mayo Clinic Laboratories
Reference Range Information
Performing Location Reference Range​​
Mayo Clinic Laboratories​ ​The presence or absence of BCR/ABL1 mRNA fusion form e13/e14-a2 producing the p210 fusion protein is identified. If positive, the quantitative level is reported as the normalized ratio of BCR/ABL1 (p210) to endogenous ABL1 mRNA with conversion to a percentage referenced to the international scale (IS), on which 0.1% BCR/ABL1:ABL1 (also represented on a log scale as Molecular Response 3, or MR3) is designated as a major molecular response (MMR) threshold.
Interpretation
 An interpretive report will be provided. When BCR/ABL1 mRNA is present, quantitative results are reported on the international scale (IS), established from data originally reported in the IRIS (International Randomized Study of Interferon versus STI571) trial involving newly diagnosed chronic myeloid leukemia patients. Using the IS, a result of less than 0.1% BCR/ABL1 (p210):ABL1 is equivalent to a major molecular remission. This value is also designated on a log scale (Molecular Response, MR) as MR3. For further discussion of the international scale, see Clinical References.
Outreach CPTs
CPT Modifier
(if needed)		 Quantity Description Comment​​s
81206​ ​ ​ ​ ​
Synonyms/Keywords
Acute lymphoblastic leukemia (ALL)
Acute myeloid leukemia (AML)
B lymphoblastic leukemia (B-ALL)
T lymphoblastic leukemia (T-ALL)
BCR-ABL1
BCR ABL
BCR/ABL
Chronic myelogenous leukemia (CML)
Philadelphia chromosome, Ph bone marrow/blood
t(9;22)
Tyrosine kinase inhibitor (TKI) therapy monitoring, PCR
Ordering Applications
Ordering Application Descripti​​on
Clinical Order Manager​ ​BCR/ABL, p210, Qnt Therapeutic
If the ordering application you are looking for is not listed, contact your local laboratory for assistance.
Specimen Requirements
Fasting Required Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)		 Pediatric Minimum Volume
​​(no repeat)
​​​No ​Whole Blood ​EDTA Lavender Top Tube (LTT) ​ACD Yellow Top Tube ​10 ml ​4 mL ​
​                                                                                        OR
​No ​Bone Marrow ​EDTA Lavender Top Tube (LTT) ​ACD Yellow Top Tube ​3 mL ​1 mL ​
Collection Processing

*Due to short sample stability, DO NOT collect at a regional center on a Friday.  If collected in Marshfield on Friday, only an AM morning draw is acceptable.

Specimen MUST ARRIVE within 72 hours of collection.​ Collect and package specimen as close to shipping time as possible. Specimens greater than 3 days old at the time of receipt will be considered unacceptable.

The following information is required:

1. Pertinent clinical history including if the patient has a diagnosis of chronic myeloid leukemia or other BCR/ABL1-positive neoplasm

2. Date of collection

3. Specimen source (blood or bone marrow)

Acceptable Specimen Types
​Whole Blood OR Bone Marrow
Specimen Stability Information
Specimen Type Temperature Time​​

​Whole Blood

OR

Bone Marrow

​

​Refrigerated

(preferred)

 ​72 hours
​Room Temperature ​72 hours
Rejection Criteria
Whole Blood Gross Hemolysis​​
Bone Marrow​ ​Gross Hemolysis
Useful For
​MONITORING response to therapy in patients with chronic myeloid leukemia who are known to have the e13/a2 or e14/a2 BCR/ABL 1 fusion transcript forms
Reference Range Information
Performing Location Reference Range​​
Mayo Clinic Laboratories​ ​The presence or absence of BCR/ABL1 mRNA fusion form e13/e14-a2 producing the p210 fusion protein is identified. If positive, the quantitative level is reported as the normalized ratio of BCR/ABL1 (p210) to endogenous ABL1 mRNA with conversion to a percentage referenced to the international scale (IS), on which 0.1% BCR/ABL1:ABL1 (also represented on a log scale as Molecular Response 3, or MR3) is designated as a major molecular response (MMR) threshold.
Interpretation
 An interpretive report will be provided. When BCR/ABL1 mRNA is present, quantitative results are reported on the international scale (IS), established from data originally reported in the IRIS (International Randomized Study of Interferon versus STI571) trial involving newly diagnosed chronic myeloid leukemia patients. Using the IS, a result of less than 0.1% BCR/ABL1 (p210):ABL1 is equivalent to a major molecular remission. This value is also designated on a log scale (Molecular Response, MR) as MR3. For further discussion of the international scale, see Clinical References.
For more information visit:
Performing Laboratory Information
Performing Location Day(s) Test Performed Report Available Methodology/Instrumentation​​
Mayo Clinic Laboratories​ ​Monday through Friday ​3 to 6 days Quantitative Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
Reference Lab
Mayo Clinic Laboratories
For billing questions, see Contacts
Outreach CPTs
CPT Modifier
(if needed)		 Quantity Description Comment​​s
81206​ ​ ​ ​ ​
For most current information refer to the Marshfield Laboratory online reference manual.